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Abstract
Background: This analysis assessed the epidemiological and economic impact of quadrivalent human
papillomavirus (HPV4: 6/11/16/18) vaccination in Estonia.
Methods: A dynamic transmission model was used to assess the epidemiological and economic impact of the
routine vaccination of 12-year-old girls with a HPV4 vaccine in preventing cervical cancer, cervical intraepithelial
neoplasia (CIN) grades 1, 2 and 3 and genital warts.
Results: The model projected that at year 100, HPV4 vaccination would lead to a reduction of HPV 16/18 related
cervical cancer incidence and deaths by over 97% and the incidence of HPV 6/11 related genital warts among
Estonian women and men by over 94% and 81%, respectively. The incremental cost-effectiveness ratio of the HPV4
vaccination strategy was € 4,889 per QALY gained over a time horizon of 100 years.
Conclusions: Routine vaccination of 12-year-old girls with HPV4 vaccine appears to be cost-effective in Estonia, in
addition to providing both short term and long term health gains.
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Background
Evaluations of the cost-effectiveness of high-risk human
papillomavirus (HPV) vaccination as a cervical cancer
prevention measure are mostly limited to countries in
Western Europe and North America [1]. Few studies
have assessed the cost effectiveness of HPV vaccination in
Central and Eastern European countries [2-5]. Countries
in this region tend to have less-developed cervical cancer
screening programs, and subsequently have considerably
higher age-standardized cervical cancer incidence rates
(14.7 per 100,000, 2008) than those in Western Europe
(6.9 per 100,000, 2008) or North America (5.7 per
100,000, 2008) [6].
In Estonia the cervical cancer incidence (age-standardized
incidence rate 15.8 per 100,000, 2008) and mortality (age-
standardized mortality rate 6.2 per 100,000, 2008) are sig-
nificantly higher than in many developed countries
including neighboring Scandinavian countries [6]. Current
coverage with any type (opportunistic or systematic) of
cervical cytology (PAP smear) testing-based cervical can-
cer screening is relatively high (3-year coverage of ~72%)
in the country [7]. Systematic screening implemented in
parallel with ongoing opportunistic screening was intro-
duced in 2006 [8] but has achieved only limited coverage
(24% of the target population, women aged 30 to 59 years
in 2009). Both bivalent and quadrivalent HPV (HPV2 and
HPV4) vaccines are approved for use in Estonia [9].
This study investigated the clinical benefits and eco-
nomic consequences of routine quadrivalent HPV vac-
cination of females by the age of 12 years in Estonia.
Specifically, this study was designed to evaluate the
potential impact in Estonia of prophylactic quadriva-
lent HPV vaccination on the incidence of cervical
intraepithelial neoplasia (CIN), cervical cancer, genital
warts, and cervical cancer mortality when added to
the current cervical cancer screening and standard of
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Methods
We adapted a previously developed HPV dynamic math-
ematical model to Estonia (Elbasha & Dasbach, 2010:
[10]). Details of the model structure and equations have
been published previously [10]. Individuals enter the
model as they are born, move between successive age
groups at an age- and gender-specific rate per year, and
exit the model as they die. The model estimates health
benefits and costs in a dynamic population. The model
also estimates the impact of vaccination on vaccinees
and their contacts (via herd immunity impact).
Demographic and epidemiological model
The model simulated aging and all-cause mortality over
time within the Estonian population. The model simu-
lated the transmission of HPV infection within the
population as determined by the course of sexual
mixing, a feature which allows for estimating both the
direct and indirect (i.e. herd immunity) benefits of vac-
cination. Hence, the model required inputs on sexual
activity risk groups in the population.
Vaccination and screening strategies
In the model, it is assumed that vaccination occurs prior
to sexual debut and would consist of the three
recommended doses, and the vaccination would confer
type-specific protection. Other parameters subjected to
greater uncertainty such as vaccination coverage and
duration of protection were further explored in the sen-
sitivity analysis. The model incorporates vaccine efficacy
from the most recent clinical trials. The prophylactic
vaccine efficacy against transient HPV 6, 11, 16 and 18
infections was assumed to be 76.1%, 76.1%, 76.0%, and
96.3%, respectively (Merck & Co., Inc. Unpublished data
2009). The vaccine efficacy against persistent HPV 16
and 18 infections was assumed to be 98.8% and 98.4%,
respectively.
In both the vaccinated and unvaccinated cohorts,
screening was modelled according to the actual current/
routine Estonian cervical cancer screening practice.
Model inputs: values and sources
The model requires input values for demographic, be-
havioural, epidemiological, screening, treatment, vaccine,
and economic parameters (see Additional file 1: Tables
A1-A13).
When available, we used data from Estonia as inputs,
otherwise we used the default data in the model pub-
lished for the US [10] (inputs not presented in this
report are available in the online supplement of Elbasha
& Dasbach, 2010 [10]).
The Estonian Health Insurance Fund (HIF) database
was used as the source for health care utilization data,
HPV disease occurrence and health care costs (see
Additional file 1: Tables A1-A13). Health insurance in
Estonia is funded through a compulsory scheme under
which employers are obliged by law to pay social and
health insurance taxes for their employees. Self-employed
people pay a social tax based on their income. Individuals
whose social/health insurance tax is paid by their em-
ployer or who pay it themselves are considered to be cov-
ered by health insurance ("the insured") and are members
of the HIF. As of 31 December 2008, 1,281,718 people
were registered as insured by the HIF representing 95.6%
of the Estonian population [11]. The HIF database is a “re-
imbursement database” containing information on ambu-
latory and in-patient/hospital care as well as reimbursed
pharmaceuticals. As HIF reimburses health care providers
on a fee-for-service basis and, the database is considered
to be relatively complete.
Data sources:
1) Demographic data (population size and
composition, age and gender specific mortality)
was taken from Statistics Estonia (Statistics
Estonia, [12]) (Table A1);
2) Sexual behaviour data was derived from the
Estonian Health Interview Survey 2006 [13].
Estimates on the mean number of sexual partners
per year by gender and age group were used and
categorised as: low (0–1 per year), medium (2–4
per year), and high (5+ per year). The parameter
was modified for model calibration purposes. The
data on mean partners by age categories were
changed so that the model projected a close
estimate of the observed cervical cancer incidence
and deaths in the Estonian population (Tables A3,
A4 and section on Validation Analyses for more
details);
3) The age and stage-specific cervical cancer mortality
was assumed to be the same as in the US [14]
(Table A2);
4) Screening data (cervical cancer screening rate by age
group, % per year, proportion of women with a
follow-up screening following an abnormal PAP)
(Table A5);
5) Treatment variables (Table A5):
(i) proportion of women with cervical cancer who
develop symptoms and seek care, by cancer stage
– Estonian cancer registry;
(ii) proportion of CIN/carcinoma in situ (CIS)
treated, by stage – expert opinion and literature
[10]. Based on local data (expert opinion), it was
assumed that 50% of diagnosed CIN1 cases and
100% of diagnosed CIN2/CIN3 cases receive
treatment; and
(iii) hysterectomy rates by age group, % per
year – based on the data from HIF;
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6) Economic variables:
(i) direct medical costs of interventions were
estimated using the national tariffs of the HIF for
2011 were reported in euros. Euro is the national
currency in Estonia.
(ii) costs of diagnosing and treating HPV disease
(genital warts, cervical cancer screening and visit,
colposcopy, biopsy, CIN 1,2,3 episode-of-care,
cervical cancer (local, regional, distant) episode
of care) – data from HIF (Table A6; A8—A13);
(iii) vaccine cost: A cost of €59.00 per dose for the
HPV4 vaccine was used, based on assumptions
made in an earlier published analysis for Estonia
[15] (Table A4)
7) Vaccine strategy variables are based on the following
assumptions and data sources:
(i) HPV4 coverage of 85% of females age 12. This
was set slightly below the 91.2% reported in 2010
for coverage with two doses of measles, mumps,
and rubella vaccine (MMR), the second dose of
which is administered to 13- to 14-year-old
adolescents within the state calendar vaccination
programme and via the school health system [16];
(ii)100% adherence with the 3-dose regimen;
(iii) Vaccine will be delivered through the existing
school-based delivery system, similar to the
current MMR regimen;
(iv) Lifetime duration of protection was assumed in
base scenarios. Effects of different lengths of
duration were tested in a sensitivity analysis.
Cost effectiveness analysis
To calculate the cost-effectiveness of the vaccination strat-
egy in preventing disease with respect to costs, we used
the total discounted costs and effects (i.e. quality-adjusted
life years, QALYs) accrued over a 100-year period with
and without vaccination. In addition, the incremental
costs incurred to achieve the incremental benefits by vac-
cination were calculated and the ratio of the incremental
costs to incremental QALYs gained (i.e., the incremental
cost-effectiveness ratio, ICER) are presented.
QALYs were estimated based on health utilities from
the U.S. (Table A7). In addition to utilities for HPV
disease states, age and gender-specific utility weights
were also incorporated for individuals without HPV
disease to account for the impact of co-morbid condi-
tions (Table A7).
Both costs and medical outcomes were discounted at
an annual rate of 3% [17,18].
Model validation
As described above, the model was calibrated for Estonia
using sexual activity and cancer detection rate parame-
ters. We assessed the predictive validity of the model by
comparing model predictions with observed data on the
age specific incidence of cervical cancer and cervical
cancer deaths in Estonia.
Sensitivity analyses
The cost effectiveness analysis is based on a number of
assumptions. Due to uncertainty in some of these as-
sumptions, several one-way sensitivity analyses were car-
ried out. The parameters included duration of vaccine
protection (20 years), vaccine coverage rates (70%, 95%),
HPV disease diagnosis and treatment costs (+/−20%),
vaccine cost per dose (+/−10%), discount rate (5%), and
QALY weights. We also examined a scenario assuming
no quality of life adjustments (cost per life years saved).
Additionally, we examined the impact of HPV 6 and 11
protection in HPV4 on cost-effectiveness by running a
scenario without the HPV 6 and 11 protection.
We also examined the cost-effectiveness of HPV vac-
cination under a hypothetical improved screening pro-
gram. This hypothetical program was assumed to have
immediate coverage of 95% (compared with the current/
routine coverage of 72%) and the same age-specific
annual rate as the base case scenario. Hypothetical im-
proved screening independently gradually reduced the
HPV16/18-related cervical cancer incidence to ~6 per
100,000 per year (age-standardized) at the steady-state in
the model, about 100 years after screening had been ini-
tiated in the population. This steady-state cervical cancer
incidence corresponded to ~ 8 per 100,000 per year of
any HPV type (based on the assumption of 76% contri-
bution of HPV 16/18 to cervical cancer; [6]) and mir-
rored the current cervical cancer incidence observed in
the Western Europe [19].
Results
Model validation
The overall incidence of HPV type-16/18-related cervical
cancer projected from the model was 11.8 per 100,000
females and cervical cancer mortality was 3.4 per 100,000
females. This is consistent with the overall cervical cancer
incidence of 15.8 and mortality of 4.7 per 100,000 females
[6], of which approximately 76% (i.e. 12.1 and 3.6, respect-
ively) is thought to be HPV16/18-related [6].
The projected incidence of HPV 6/11-related genital
warts (GW) treated was about 110 cases per 100,000 for
females and 45 per 100,000 for males. The GW treat-
ment incidence differed by gender. We incorporated this
gender difference in the model by changing the propor-
tion of those who received treatment among those who
developed GW. This is consistent with overall GW treat-
ment incidence of 123/50 (females/males) per 100,000
(HIF database – ICD-10 diagnosis code A63.0, average
annual incidence of 7 years over period of 2004–2010),
of which approximately 90% (i.e. 111/45, females/males
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respectively, per 100,000) is thought to be related to
types 6/11 [10].
Clinical / health effects
Annual incidence of disease cases
Figures 1, 2, and 3 present the changes in occurrence of
genital warts (among women and men), CIN2, 3, and
cervical cancer incidence, respectively.
The effect of vaccination was to progressively reduce
the incidence of cervical cancer cases and deaths until
the system approached a steady state, about 100 years
after vaccination has been initiated in the population.
Compared with no vaccination, the vaccination reduced
the incidence of 16/18-related cervical cancer cases and
deaths by over 97% by year 100. At year 50, the vaccin-
ation strategies reduced the incidence of 16/18-related
cervical cancer cases by 59% (no vaccination vs vaccin-
ation: 11.8 vs 4.85 per 100 000), and deaths by 50% (no
vaccination vs vaccination: 3.42 vs 1.71 per 100 000).
Numbers of HPV 16/18-related cervical cancer cases
were halved in the vaccinated group by year 46.
A similar dynamic was observed for the reductions in
CIN 2/3, CIN 1, genital warts-female and genital warts-
male cases as displayed in Figures 1 and 2. These curves
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Figure 1 Incidence of HPV 6/11 related genital warts among men and women per 100 000 population over time, Estonia.
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Figure 2 Incidence of HPV 16/18-related CIN 2/3 per 100 000 population over time, Estonia.
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share similar qualitative features with those of cervical
cancer, but are shifted to the left compared with the cer-
vical cancer curves (Figure 3).
At year 100, the model predicted that the vaccination
strategy would provide over 98% relative reduction in
the incidence of 6/11/16/18-related CIN 2/3 and CIN 1,
and 94% and 81% reductions in HPV 6/11 related genital
warts in females and males, respectively. The number of
6/11/16/18-related cases of CIN2/3, CIN1, genital warts-
female, and genital warts-male were halved by year 29,
26, 16, and 19.
Cumulative impact in population over 100 years
Adding vaccination to the cervical cancer screening led
to significant health benefits. The model showed reduc-
tions over 100 years in: HPV 16/18 related deaths (50%);
cervical cancer incidence (52%); CIN 2/3 (68%); and
genital wart incidence among women (79%) and men
(67%) (over 100 years) (Table 1).
Economic impact and cost effectiveness analysis
Introduction of vaccination program will lead to a 29%
reduction of disease costs over 100 years. Per person
discounted costs and effects (i.e., QALYs) accrued
over a 100-year period with and without vaccination
strategy, incremental costs, and incremental QALYs,
and the incremental cost effectiveness ratio are pre-
sented Table 2. The incremental cost-effectiveness ra-
tio (ICER) for routine vaccination of girls by age 12
was €4,889/QALY.
Sensitivity analysis
The ICER increased when we excluded protection
against HPV 6/11 disease (€ 5771 per QALY) or limited
the time of vaccine protection to 20 years (€ 8090 per
QALY) (Table 3). The ICER was € 6167 per QALY under
the assumption of hypothetical (improved) cervical can-
cer screening in Estonia. The rate of discounting was
one of the influential factors affecting the results. The
ICERs did not vary by the changes to health care costs
related to HPV disease diagnosis and treatment.
Discussion
This is one of the first studies to examine the potential
impact of HPV2 and 4 vaccination in Estonia [15]. The
incremental cost-effectiveness ratio of the vaccination
compared with no vaccination was €4,889 per QALY
gained over a time horizon of 100 years. Given that base
case as well as all scenarios tested in sensitivity analysis
remained below one GDP per capita in Estonia (2011:
€11,900 [20]) HPV vaccination can be deemed cost
effective (based on WHO recommendations on cost ef-
fectiveness [21]) in Estonia.
The analysis of HPV vaccination by Liiv et al. [15]
derived a cost effectiveness estimate of €10,019 /QALY
(at the 3% discount rate). Variations in the ICER esti-
mates between the current work and that of Liiv et al.
are probably explained by the different models used
(dynamic transmission model incorporating the effect of
herd protection vs Markov model) and several differ-
ences in the assumptions made (non-life-long immunity
and booster dose inclusion; higher (95%) vaccine









0 10 20 30 40 50 60 70 80 90 100

















Figure 3 Incidence of HPV 16/18-related cervical cancer per 100 000 population over time, Estonia.
Table 1 Cumulative reduction in cases (percent) of HPV










31 (2%) 654 (17%) 4103 (52%)
HPV16/18-related CIN2/3 1390 (12%) 9541 (40%) 32508 (68%)
HPV16/18-related CIN1 554 (15%) 3391 (45%) 10760 (71%)
HPV6/11-related CIN1 271 (32%) 1016 (61%) 2591 (77%)
HPV6/11-related genital
warts (female)
6663 (36%) 23246 (63%) 58035 (79%)
HPV6/11-related genital
warts (male)
2092 (28%) 7873 (53%) 20047 (67%)
* Percentages rounded to nearest 1; ** Cases rounded to nearest 1.
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coverage; lower proportion (70%) of HPV 16/18 related
cervical cancer contribution in Liiv et al.). Such factors
are informative for contextualizing the results.
However, both studies are in agreement with the re-
cent systematic review [1] in concluding that while
different model structures, input parameters and base-
line assumptions have been used to assess the cost ef-
fectiveness of HPV vaccination, studies that focused
on female-only vaccination programmes usually find
this intervention to be cost effective compared with
cervical cancer screening alone [1].
Our results document significant health effects related
to the combined use (HPV4 vaccination + cervical can-
cer screening) of cervical cancer prevention methods.
The model projected that at year 100, HPV4 vaccination
would lead to a relative reduction of HPV 16/18 related
deaths and cervical cancer incidence by over 97% and
the incidence of HPV 6/11 related genital warts among
Estonian women and men by over 94% and 81%, re-
spectively. In addition, there are relevant immediate
public health impacts of HPV4 vaccination on genital
warts among both women and men. Every year, approxi-
mately 751 women and 276 men receive treatment for
genital warts in Estonia (based on HIF treatment statis-
tics during 7 years from 2004–2010, ICD 10, diagnosis
code A63.0, data not shown). Our model projected a
substantial reduction in the incidence of genital warts in
the first 25 years.
Based on the sensitivity analysis, the incremental costs
per QALY are about 20% higher if vaccination is
implemented against a background of improved cervical
cancer screening. We found that the cost-effectiveness
ratio was heavily impacted by the discount rate and
health utility values used. Assuming a limited duration
of vaccine protection and reducing the costs of the vac-
cine led to modest changes in ICER in opposite direc-
tions (i.e. limiting duration increased ICER and reducing
costs decreased ICER).
Our findings should be interpreted with due consider-
ation for a number of limitations. First, we did not con-
duct an in-depth literature review to obtain data on the
natural history of site- and type-specific HPV infection
and disease or on health utility requirements of HPV
disease states. Instead, we abstracted relevant data from
published studies [10] and we also assessed the cost
per life year saved with no quality of life adjustments
in the sensitivity analysis. However, for most of the key pa-
rameters Estonian specific data were used, and the model
was calibrated using cervical cancer incidence/mortal-
ity in Estonia. Second, our model is based on a num-
ber of efficacy assumptions regarding transient and
persistent infection which are not completely available in
the published literature. Third, we did not incorporate
additional potential benefits of protecting against HPV
diseases such as vulvar, vaginal, and anal dysplasia/
cancers in this analysis. Data from clinical trials sup-
ports the efficacy of the vaccine against these diseases
[22-24]. This potentially underestimates the benefits
of vaccination. On the other hand, the duration of
vaccine protection is uncertain (although we assumed
life-long vaccine protection in the base case). Further,
the model simulates only the heterosexual transmission of
Table 2 Cost effectiveness of HPV vaccination in Estonia, model estimates
Discounted total Incremental
Costs/person (€)* QALY/person (year)** Costs/person (€)* QALY/person (year)** Costs/QALYs (€/year)***
No vaccination 126.29 27.09184 – – –
Routine vaccination 152.79 27.09726 26.5 0.00542 4889
*Costs rounded to 0.01; **QALYs rounded to 0.00001; ***Costs/QALYs rounded to 1.
Table 3 Sensitivity analysis: incremental cost-






Under hypothetical improved cervical screening program** 6167
Vaccine characteristics
Assuming no HPV 6/11 protection 5771
Duration of protection = 20 years 8090
Vaccination characteristics
Low vaccine coverage (70%) 4444
High vaccine coverage (95%) 5212
Costs characteristics
Cost of diagnosis and treatment +20% 4744
Cost of diagnosis and treatment −20% 5037
Cost of vaccine - 10% 4351
Cost of vaccine + 10% 5454
Health utility values
Cost per life year saved (no quality of life adjustments) 6746
Discount rate
Discount rate 0% 1517
Discount rate 5% 11148
* HPV6/11/16/18 related cervical cancer and genital warts.
**Vaccination program introduced alongside hypothetical improved cervical
screening program.
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HPV and does not incorporate transmission between
homosexual and heterosexual individuals. Only direct
medical costs were included in the model, ignoring
potential savings in or outside the health care sector.
Excluding indirect costs from the analysis most likely
leads to undermining of the vaccination effect, given
that preventing the disease (cervical cancer) adds to
the productive activity. Importantly, the model could
not distinguish systematic from opportunistic cervical
cancer screening. Systematic screening is generally
more effective and cost-effective than opportunistic
screening: countries that have organised screening
programmes have much lower lifetime testing and subse-
quent treatment rates than those with only opportunistic
screening [25-27]. However, we used sensitivity analysis to
evaluate the potential effect of vaccination in combination
with the hypothetical/improved (systematic) screening.
Our finding of a higher ICER value in the case of hypo-
thetical/improved screening is in agreement with the
current understanding of HPV disease and prevention
(improved screening results in a lower incidence of cer-
vical cancer, therefore a higher ICER for vaccination strat-
egy). Last but not least, our sensitivity analyses were
limited to the inputs related to vaccine properties and
coverage, US based health utilities, health care (diagnosis,
treatment) costs, and discount rate and did not include all
demographic, behavioural, clinical, and other natural his-
tory parameters. This was done mainly to manage com-
plexity in the analysis and obtain results in a timely
manner for policy evaluations. As a result, the uncertainty
results do not reflect the full range of possible factors.
Finally, there are several unresolved issues for success-
ful implementation of cervical cancer prevention, includ-
ing delineating the optimum set of components (primary
prevention, screening, vaccination) to reduce cervical
cancer incidence and mortality. Mathematical modelling
studies and statistical evidence synthesis are methods
that are best suited to investigating the optimal combi-
nation of different cervical cancer prevention strategies
and should be developed to guide policy decisions about
cancer control.
Conclusions
In general, routine vaccination of 12-year-old females
appears to be cost-effective in Estonia and may provide
both short-term and long-term health gains.
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